Topical SGX302 for Mild-to-Moderate Psoriasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
PsoriasisPlaque PsoriasisPsoriasis Vulgaris
Interventions
DRUG

Hypericin

SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.

DRUG

Placebo

Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.

Trial Locations (1)

92123

RECRUITING

Therapeutics Clinical Research, San Diego

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Soligenix

INDUSTRY